Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
WANBURY | NSE
-2.84
-1.11%
Healthcare
Drug Manufacturers-Specialty & Generic
31/03/2024
18/09/2024
253.35
260.00
260.00
250.00
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology orthopedics heamatinics anti-diabetic nutraceuticals gastro intestinal stroke surgery antibiotics cough and cold solutions anti-inflammatory analgesics and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic anti-analgesic anti-depressant anti-histaminic anti-inflammatory anti-arthritis anti-thrombotic anti-epileptic and anti-hypertensive therapeutic areas. Wanbury Limited also exports its products. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. The company was incorporated in 1988 and is headquartered in Navi Mumbai India.
View LessPositive Momentum
Low Market Beta (-0.4 to 0.8)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
50.3%1 month
47.9%3 months
49.5%6 months
48.3%16.51
-
29.05
4.17
0.34
9.39
1.61
-
683.94M
8.30B
99.31M
-
5.86
-78.30
-10.40
51.37
-
-
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
45.00
Range1M
81.80
Range3M
116.63
Rel. volume
0.38
Price X volume
15.74M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Albert David Ltd | ALBERTDAVD | Drug Manufacturers-Specialty & Generic | 1479.35 | 8.44B | -0.14% | 10.74 | 0.87% |
Ind-Swift Laboratories Limited | INDSWFTLAB | Drug Manufacturers-Specialty & Generic | 137.79 | 8.14B | -1.82% | 2.10 | 1.78% |
Kilitch Drugs (India) Limited | KILITCH | Drug Manufacturers-Specialty & Generic | 370.4 | 5.99B | -1.71% | 50.24 | 17.95% |
Medicamen Biotech Limited | MEDICAMEQ | Drug Manufacturers-Specialty & Generic | 463.15 | 5.84B | -2.80% | 72.99 | 15.37% |
Zim Laboratories Limited | ZIMLAB | Drug Manufacturers-Specialty & Generic | 112.64 | 5.52B | -0.58% | 31.56 | 45.58% |
Venus Remedies Limited | VENUSREM | Drug Manufacturers-Specialty & Generic | 347.15 | 4.67B | -1.00% | 17.16 | 8.48% |
Brooks Laboratories Limited | BROOKS | Drug Manufacturers-Specialty & Generic | 156.7 | 4.11B | 0.00% | n/a | 8.60% |
Medico Remedies Limited | MEDICO | Drug Manufacturers-Specialty & Generic | 46.5 | 3.72B | 1.75% | 41.94 | 15.37% |
Par Drugs And Chemicals Limited | PAR | Drug Manufacturers-Specialty & Generic | 238.85 | 3.00B | -1.34% | 22.25 | 0.00% |
Alpa Laboratories Limited | ALPA | Drug Manufacturers-Specialty & Generic | 115 | 2.49B | -3.18% | 14.11 | 3.45% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Bhagyanagar India Ltd | BHAGYANGR | Copper | 106.49 | 3.41B | -2.42% | 34.15 | 52.08% |
Touchwood Entertainment Limited | TOUCHWOOD | Advertising Agencies | 172.05 | 1.91B | 1.72% | 49.20 | 4.88% |
Cubex Tubings Limited | CUBEXTUB | Copper | 96.65 | 1.38B | -1.91% | 34.07 | 21.78% |
Madhav Copper Limited | MCL | Copper | 36.91 | 1.03B | -1.89% | n/a | 32.70% |
Heads UP Ventures Limited | HEADSUP | Apparel Retail | 14.89 | 336.84M | -5.34% | n/a | 0.00% |
Suumaya Industries Limited | SUULD | Apparel Retail | 5.05 | 303.87M | -0.98% | n/a | -118.72% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 9.39 | - | Cheaper |
Ent. to Revenue | 1.61 | - | Cheaper |
PE Ratio | 16.51 | 47.84 | Cheaper |
Price to Book | 29.05 | 6.55 | Expensive |
Dividend Yield | - | - | - |
Std. Deviation (3M) | 49.46 | - | Riskier |
Debt to Equity | 4.17 | 0.34 | Expensive |
Debt to Assets | 0.34 | 0.17 | Expensive |
Market Cap | 8.30B | - | Emerging |